Robotrak Medical Technology Co., Ltd. ("Robotrak"), a leading innovator in ophthalmic imaging and treatment systems, today announced the successful completion of its Series C funding round. The investment consortium includes Nanjing New Industrial Investment Group, Ophtec (a subsidiary of OuPu Kangshi), and TaiYu Capital. The proceeds will accelerate product development, international market expansion, and the commercialization of Robotrak's next-generation ophthalmic technologies.

Founded in 2017, Robotrak specializes in cutting-edge ophthalmic diagnostic and therapeutic solutions. Its flagship product, Mona IV Adaptive Optics Retinal Imaging System, leverages advanced optical correction technology to achieve 0.7μm resolution—approximately 10 times sharper than conventional systems—enabling clinicians to visualize individual photoreceptors, capillaries, and nerve fibers. This breakthrough supports early detection of inherited retinal diseases and diabetic retinopathy, potentially transforming disease management paradigms.

Complementing the Mona IV, Robotrak's Aglaia 577 Intelligent Laser Navigation System integrates ultra-widefield imaging, eye-tracking, and AI-assisted treatment planning, significantly enhancing precision in retinal laser therapy. Additionally, the company has developed a myopia management portfolio, establishing a comprehensive eye care ecosystem from screening to intervention.

Robotrak's products have been adopted by top-tier hospitals in China and international institutions, with recent installations including Washington University's Vision Research Center. The Series C funding will further strengthen Robotrak's global commercialization efforts, positioning its high-precision ophthalmic platforms as competitive alternatives in international markets.

"Our mission is to redefine ophthalmic diagnostics through engineering innovation," said a Robotrak spokesperson. "This investment validates our progress in bridging research-grade imaging with clinical practice, and we're poised to expand access to these technologies worldwide."

June 25, 2025, MedChina